Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas
David R. Minor, Kevin B. Kim, R. Krishna M. Karuturi, Mohammed Kashani-Sabet · 2023
Read Extended long-term follow-up of metastatic melanoma patients treated with immunotherapy: late relapses and second primary melanomas by David R. Minor, Kevin B. Kim, R. Krishna M. Karuturi, Mohammed Kashani-Sabet (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10725969.txt.
Description
David Minor and co-authors followed patients whose metastatic melanoma had melted away under immunotherapy, to see how safe the victory stays over decades. Most trials stop watching after five years, leaving late relapse rates guesswork. The team found fifty-nine patients alive and in remission five years after starting interleukin-2 or checkpoint inhibitor treatment. They traced their later course, a median of thirteen years in total.
Four patients, about seven percent, relapsed at five, eight, fifteen, and seventeen years; three of them remain alive. Only one new primary melanoma appeared across 690 patient-years. The authors estimate that patients still in remission at five years hold roughly eighty-five percent progression-free survival at twenty years. They argue follow-up can relax but should not vanish.
Catalog record
| CREATOR | David R. Minor, Kevin B. Kim, R. Krishna M. Karuturi, Mohammed Kashani-Sabet |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 20 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |